10-Q quarterly report · filed Nov 3, 2026

MADRIGAL PHARMACEUTICALS, INC. (MDGL) Q3 2026 10-Q Quarterly Report

Short answer

MADRIGAL PHARMACEUTICALS, INC. (MDGL) filed its Q3 2026 10-Q quarterly report on Nov 3, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $431M (up 50.1% year over year) with net income of $55M.

Q3 2026 key financials · XBRL

Revenue
$431M
+50.1% YoY · +18.4% QoQ
Net income
$55M
+148.6% YoY · +195.7% QoQ
Operating margin
13.0%
EPS (diluted)
$1.92
+137.6% YoY · +196.5% QoQ

Source: XBRL data from the MADRIGAL PHARMACEUTICALS, INC. (MDGL) Q3 2026 10-Q on SEC EDGAR. USD.

MADRIGAL PHARMACEUTICALS, INC. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Revenue $431.3M, up $144.0M YoY, driven by increased U.S. Rezdiffra demand
  • Operating margin 13.0% vs negative 39.7% YoY, with operating income $56.0M vs loss of $114.0M
  • Rezdiffra, sole reported product, generated $431.3M revenue and $37.8M cost of sales
  • Cash, restricted cash and marketable securities $961.8M vs $988.6M at December 31, 2025
  • Operating cash use $23.6M year-to-date, with $320.2M investing inflow and $15.4M financing inflow

Risk Factors

  • Newly highlighted clinical-trial risk: FDA, EMA conditions, enrollment delays, supply shortages, or adverse effects could postpone approvals and commercialization
  • Most materially updated financial risk: $2,187.4 million accumulated deficit despite $55.4 million quarterly net income
  • Regulatory risk: FDA-required Rezdiffra post-marketing commitments and clinical trials could increase costs or delay commercialization
  • Operational risk: Delayed trial completion could allow competitors to commercialize products first
  • Liquidity risk: $961.8 million in cash, restricted cash, and marketable securities as of September 30, 2026

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other MADRIGAL PHARMACEUTICALS, INC. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.